Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Company Deals Digital

SciClone Pharmaceuticals Partners with JD Healthcare to Pioneer Integrated Immune Health Management Model

Fineline Cube Apr 24, 2026
Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Fineline Cube Apr 23, 2026
Company Deals

AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio

Fineline Cube Apr 23, 2026
Policy / Regulatory

NMPA Suspends Colchicine API Imports from Indian Manufacturers Alkaloids Bioactives and Alchem International Over Change Management Violations

Fineline Cube Apr 23, 2026
Company Drug

China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis

Fineline Cube Apr 24, 2026
Company Drug

AbbVie Receives FDA Complete Response Letter for TrenibotE with Manufacturing Clarifications Requested

Fineline Cube Apr 24, 2026
Company Drug

NMPA Grants Marketing Approval for Hui Sheng Bio-pharmaceutical’s Janagliflozin

Fineline Cube Jan 22, 2024

The National Medical Products Administration (NMPA) has granted marketing approval for Hui Sheng Bio-pharmaceutical Co.,...

Company Drug

Novartis Lutathera Combo Therapy Shows Significant Progress in GEP-NETs

Fineline Cube Jan 22, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced preliminary results from a Phase III study...

Company Drug

AstraZeneca’s Imfinzi Meets Primary Endpoint in Hepatocellular Carcinoma Trial

Fineline Cube Jan 22, 2024

UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced the successful completion of the primary endpoint...

Company Drug

J&J’s Balversa Receives Full FDA Approval for Urothelial Carcinoma Treatment

Fineline Cube Jan 22, 2024

The US Food and Drug Administration (FDA) has converted the 2019 accelerated approval for Johnson...

Policy / Regulatory

Shandong Province Launches Initiatives to Accelerate Pharmaceutical Innovation and Growth

Fineline Cube Jan 22, 2024

Shandong province has announced a comprehensive set of measures aimed at optimizing review and approval...

Company

Everest Medicines Projects Sharp Revenue Increase for 2023 on New Product Launches

Fineline Cube Jan 22, 2024

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced a preliminary revenue forecast for...

Company Drug

Uni-Bio Science Group Wins NMPA Nod for Generic Forteo Injection for Osteoporosis

Fineline Cube Jan 22, 2024

Hong Kong-listed biopharmaceutical company Uni-Bio Science Group Ltd (HKG: 0690) has announced that it has...

Company Deals

Endoso Life Raises Over $14 Million in Series A to Expand Endoscope Product Lines

Fineline Cube Jan 22, 2024

Endoso Life, a developer of high-end medical endoscope systems headquartered in Hangzhou, has reportedly secured...

Company Deals R&D

Convalife Pharmaceuticals and Divamics Inc. Join Forces to Advance Drug Discovery with AI

Fineline Cube Jan 22, 2024

Convalife Pharmaceuticals, a Shanghai-based clinical pharmaceutical company, and Divamics Inc., a Suzhou-headquartered biopharmaceutical firm specializing...

Company Drug

Sichuan Kelun-Biotech Secures NMPA Nod for Generic Lynparza Equivalent

Fineline Cube Jan 22, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a Chinese pharmaceutical company, has announced that it...

Company

HighTide Therapeutics to Extend NASH Treatment Reach into Hebei Province

Fineline Cube Jan 22, 2024

HighTide Therapeutics Inc. (HKG: 2511), a China-based non-alcoholic steatohepatitis (NASH) drug developer that recently made...

Company Deals Digital R&D

AI-Driven Biotech Insilico Medicine Teams Up with Hutao Tech for Precision Medicine Robotics

Fineline Cube Jan 22, 2024

Insilico Medicine, a China-based biotech company driven by generative artificial intelligence (AI), has entered into...

Company Drug

InnoCare Makes Minjuvi Combo Treatment Available to Patients in China’s GBA

Fineline Cube Jan 22, 2024

InnoCare (HKG: 9969; SHA: 688428), a China-based biopharmaceutical company, has announced that the combination treatment...

Policy / Regulatory

Guangdong Aims to Boost Biomedicine Industry with Incentives and Strategic Development

Fineline Cube Jan 22, 2024

The Guangdong Provincial Development and Reform Commission has unveiled an ambitious set of measures aimed...

Company Deals

Lee’s Pharmaceutical to Develop Windtree’s Cardiovascular Drugs in Greater China

Fineline Cube Jan 19, 2024

Lee’s Pharmaceutical Ltd (HKG: 0950) has entered into a licensing agreement with US-based Windtree Therapeutics...

Company Drug

BeiGene Submits Additional Application for Tislelizumab in NSCLC in China

Fineline Cube Jan 19, 2024

BeiGene (NASDAQ: BGNE) has announced the submission of a supplementary Biologic License Application in China...

Company Medical Device

Abbott Initiates Clinical Study for Volt PFA System in Australia for Cardiac Arrhythmias

Fineline Cube Jan 19, 2024

Abbott (NYSE: ABT) has announced that the first patients have been treated with its Volt...

Company Deals

AbbVie Grants Enigma Biomedical Group Rights to Next-Generation PET Imaging Biomarkers

Fineline Cube Jan 19, 2024

AbbVie (NYSE: ABBV), a leading pharmaceutical company in the US, has licensed to Canada-based Enigma...

Policy / Regulatory

Sichuan Health Commission Issues Directive to Strengthen Oversight of External Prescriptions

Fineline Cube Jan 19, 2024

The Health Commission of Sichuan Province has issued a notification aimed at enhancing the management...

Company Deals Hospital

Shaanxi Panlong Pharmaceutical Partners with Xi’an Medical University for Multifaceted Collaboration

Fineline Cube Jan 19, 2024

Shaanxi Panlong Pharmaceutical Group Co., Ltd (SHE: 002864), a leading pharmaceutical company based in China,...

Posts pagination

1 … 402 403 404 … 656

Recent updates

  • Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline
  • Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider
  • Huadong Medicine Secures NMPA Approval for Ellansé M PCL Microsphere Filler for Temple Hollowing Correction
  • Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market
  • China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company R&D

Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline

Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Company Medical Device

Huadong Medicine Secures NMPA Approval for Ellansé M PCL Microsphere Filler for Temple Hollowing Correction

Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.